Research group - Ali Mirazimi
In our research programmes, we will examine the molecular pathogenesis mechanism of haemorrhagic fever diseases such as Crimean Congo haemorrhagic fever Virus (CCHFV) and Ebola Disease Virus (EBOV).
Increased mobility in the general population and recent climate changes affecting the geographical distribution of viral vectors, combined with animal trade, immigrations and augmented bioterrorism threats, have heightened the risk of emerging viral diseases in Europe. These changing factors highlight the need for understanding the interactions between virus-vector-animal-human in the infection cycle and for the development of new countermeasures such as antivirals and vaccines. Knowledge regarding the pathogenesis of highly emerging viruses such as Viral Hemorrhagic Fever (VHF) is very limited and in some cases completely lacking. VHF diseases are caused by a diverse set of pathogens belonging to different virus families. Some of these viruses cause very severe diseases, with fatal outcomes.
It is obvious that the knowledge of virus biology, pathogenesis, vaccine development and therapeutics is highly limited for these important bio-threat. To achieve a globally effective health programme for this disease, there is a need for synergised national and international programmes with the capability to perform modern and advanced research. Our projects are focused on multinational/institutional collaboration. The major focus of our projects are i) understanding of the role of innate immune response to molecular pathogenesis of these diseases, ii) to understand Virus-Host cell interaction (animal, insects and human cells), iii) developing vaccines against emerging viral diseases, iv) developing new therapeutic tools against emerging viral diseases and v). Developing new diagnostic tools.
Research group leader
- Swedish research Council, 2016-2018
- Formas, 2016-2019
- European Commission. H2020, 2017-2023
- Initiative medicine innovation funds, 2015-2018
- Swedish foundation for Strategic Research, 2017-2021
- The Swedish foundation for International cooperation in research and higher education, 2015-2018
Professor Friedemann Weber, Germany (Vaccine development and molecular pathogenesis)
Professor Josef Penninger, Austria (Virus-host interaction)
Professor Thomas Helleday, Scilifelab, KI (Antiviral development)
Professor Heinrich Feldmann, NIAID, NIH, (Vaccine development and molecular pathogenesis)
Professor Yee-Joo Tan, Singapore (Molecular pathogenesis)
Professor Martin Groushop, Germany, (Vaccine development)
Professor, Matti Sällberg, LABMED, KI, (Vaccine development)
Professor Nazif Elaldi, Turkey, (Vaccine development)
Professor Anna Papa, Greece, (Virus epidemiology and Diagnostic)
Professor Ola Blixt, Copenhagen (Diagnostic)
Professor. Amadou Sall, Pasture Dakar, (Diagnostic)
Professor. Noel Tordo, Pasture Guinea (Epidemiology and diagnostic)